BiondVax Pharmaceuticals (BVXV) Earns Daily News Impact Score of 0.07
Press coverage about BiondVax Pharmaceuticals (NASDAQ:BVXV) has trended somewhat positive on Monday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BiondVax Pharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 48.1020165522803 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
BiondVax Pharmaceuticals (NASDAQ BVXV) opened at 8.39 on Monday. The company has a 50 day moving average of $8.80 and a 200-day moving average of $7.15. The stock’s market capitalization is $34.08 million. BiondVax Pharmaceuticals has a 52-week low of $3.04 and a 52-week high of $10.75.
ILLEGAL ACTIVITY WARNING: “BiondVax Pharmaceuticals (BVXV) Earns Daily News Impact Score of 0.07” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/21/biondvax-pharmaceuticals-bvxv-earns-daily-news-impact-score-of-0-07.html.
BiondVax Pharmaceuticals Company Profile
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Receive News & Stock Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.